KKR Sells 5.8% Stake in JB Chemicals for Rs 1,460 Crore

By By Rediff Money Desk, New Delhi
Mar 27, 2025 20:32
Global investment firm KKR has divested a 5.8% stake in JB Chemicals & Pharmaceuticals for Rs 1,460 crore through open market transactions. The stake sale was executed through four separate transactions on the NSE.
New Delhi, Mar 27 (PTI) Global investment firm KKR on Thursday divested a 5.8 per cent stake in JB Chemicals & Pharmaceuticals for Rs 1,460 crore through open market transactions.

New York-based KKR offloaded shares in four separate transactions on the National Stock Exchange (NSE). KKR-affiliate Tau Investment Holdings Pte is the promoter of JB Chemicals & Pharmaceuticals.

As per the bulk deal data, Tau Investment Holdings sold a little over 89.83 lakh shares, amounting to a 5.78 per cent stake in Mumbai-based JB Chemicals & Pharmaceuticals.

The shares were disposed of in the price range of Rs 1,625-1,625.34 apiece, taking the combined deal value to Rs 1,459.84 crore.

After the sale, Tau Investment Holdings' stake in JB Chemicals & Pharmaceuticals has come down to 47.88 per cent from 53.66 per cent.

Meanwhile, Kotak Mahindra Mutual Fund purchased more than 12.30 lakh shares or 0.8 per cent in JB Chemicals & Pharma at an average price of Rs 1,625 per piece. The total deal value was Rs 200 crore.

Details of the other buyers of JB Chemicals & Pharmaceuticals shares could not be ascertained on the exchange.

On Thursday, shares of JB Chemicals & Pharmaceuticals plunged 6.15 per cent to close at Rs 1,603.65 apiece on the NSE.

In 2020, KKR bought a 65 per cent stake in JB Chemicals & Pharmaceuticals. Established in 1976, JB Pharma produces a range of pharmaceuticals in areas such as gastroenterology, dermatology and diabetes, etc.
Source: PTI
Read More On:
investmentbulk dealnsepharmaceuticalsstake salekkrkotak mahindra mutual fundjb chemicalsjb chemicals & pharmaceuticalstau investment holdings
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.

You May Like To Read

MORE NEWS

IndiGo Seeks Rs 900 Cr Customs Duty Refund in...

IndiGo moves Delhi HC for Rs 900 crore Customs duty refund on re-imported aircraft...

Sebi Clears Pranav Adani in Insider Trading Case

Sebi clears Pranav Adani, Adani Group director, of insider trading charges related to...

Sebi Officials & Asset Disclosure: Privacy...

Sebi officials express privacy concerns over public asset disclosure. Pandey discusses...

New Labour Codes: Supply Chains, Wages, Skilling

New Labour Codes in India aim for frictionless supply chains, universal wage coverage,...

Fidelity Buys 6.3% Stake in Meesho

Fidelity International acquires a 6.3% stake in e-commerce firm Meesho. The stake is...

Wipro & Google Cloud Deploy Gemini AI

Wipro expands Google Cloud partnership to deploy Gemini AI across operations. Jointly...

IndiGo Faces Rs 59 Cr GST Penalty, Will Contest

IndiGo slapped with nearly Rs 59 crore GST penalty for FY21. Airline to contest the...

IRFC Loan Sanctions Target: Rs 60,000 Crore in Q3

IRFC aims to surpass Rs 60,000 crore in loan sanctions by Q3, says CMD Manoj Kumar...

Paytm Invests Rs 2,250 Cr in Payments Arm

Paytm invests Rs 2,250 crore in Paytm Payments Services. RBI approves payment...

Nephrocare IPO Subscribed 13.96 Times

Nephrocare Health Services' Rs 871-cr IPO was subscribed 13.96 times on closing....

Read More »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist
© 2025 Rediff.com